HighTower Advisors, LLC - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 90 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q4 2020. The put-call ratio across all filers is 0.05 and the average weighting 0.1%.

Quarter-by-quarter ownership
HighTower Advisors, LLC ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q3 2023$64,000
+33.3%
54,071
+58.5%
0.00%
Q2 2023$48,000
-36.0%
34,116
-31.9%
0.00%
Q1 2023$75,000
+87.5%
50,116
+46.9%
0.00%
Q4 2022$40,000
+8.1%
34,116
+2.1%
0.00%
Q3 2022$37,000
-30.2%
33,4160.0%0.00%
Q2 2022$53,000
+3.9%
33,4160.0%0.00%
Q1 2022$51,000
-37.8%
33,4160.0%0.00%
Q4 2021$82,000
-2.4%
33,416
+0.3%
0.00%
Q3 2021$84,000
+82.6%
33,316
+104.2%
0.00%
Q2 2021$46,000
+21.1%
16,3160.0%0.00%
Q1 2021$38,000
+35.7%
16,3160.0%0.00%
Q4 2020$28,00016,3160.00%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q4 2020
NameSharesValueWeighting ↓
BROADWOOD CAPITAL INC 34,005,379$85,694,0004.37%
Defender Capital, LLC. 4,798,270$12,707,0004.13%
Raffles Associates 93,590$236,0000.22%
Prescott General Partners LLC 1,851,851$4,667,0000.16%
DCF Advisers, LLC 87,000$219,0000.10%
Laidlaw Wealth Management LLC 104,841$264,0000.07%
Beirne Wealth Consulting Services, LLC 45,000$113,0000.06%
Strategic Wealth Investment Group, LLC 70,625$179,0000.05%
Fort Sheridan Advisors LLC 47,931$121,0000.04%
Sightline Wealth Advisors, LLC 14,958$38,0000.03%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders